A Hubalewska–Dyde
John Wiley & Sons
e druk, 2015
9781118521533
Somatostatin Analogues – From Research to Clinical Practice
From Research to Clinical Practice
Specificaties
Gebonden, 360 blz.
|
Engels
John Wiley & Sons |
e druk, 2015
ISBN13: 9781118521533
Rubricering
Levertijd ongeveer 8 werkdagen
Samenvatting
Featuring chapters from specialists in endocrinology, physiology, pathology, and nuclear medicine, this book provides a multidisciplinary approach to a wide variety of issues concerning somatostatin and its analogues. The book:
Provides the most up–to–date coverage of somatostatin analog use in diagnostic and therapy
Integrating the specialties of endocrinology, physiology, pathology, and nuclear medicine, providing the multidisciplinary approach to the topic
Focuses on future applications, novel compounds, and areas for further research
Covers topics by authors who are renowned experts and researchers in the field
Specificaties
Inhoudsopgave
<p>Contributors viii</p>
<p>Preface xii</p>
<p>Acknowledgements xv</p>
<p>1 Somatostatin: The History of Discovery 1<br />Malgorzata Trofimiuk Müldner and Alicja Hubalewska Dydejczyk</p>
<p>2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6<br />Marily Theodoropoulou</p>
<p>3 Somatostatin Receptors in Malignancies and Other Pathologies 21<br />Marco Volante, Adele Cassenti, Ida Rapa, Luisella Righi, and Mauro Papotti</p>
<p>4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31<br />Alberto Signore</p>
<p>4.1 Somatostatin Receptor Scintigraphy SPECT 35<br />Renata Miko ajczak and Alberto Signore</p>
<p>4.2 Molecular Imaging of Somatostatin Receptor Positive Tumors Using PET/CT 55</p>
<p>Richard P. Baum and Harshad R. Kulkarni<br />4.3 Other Radiopharmaceuticals for Imaging GEP NET 75<br />Klaas Pieter Koopmans, Rudi A. Dierckx, Philip H. Elsinga, Thera P. Links, Ido P. Kema, Helle–Brit Fiebrich, Annemieke M.E. Walekamp, Elisabeth G.E. de Vries, and Adrienne H. Brouwers</p>
<p>4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86<br />Alicja Hubalewska Dydejczyk</p>
<p>4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90<br />Anna Sowa Staszczak, Agnieszka Stefa ska, Agata Jabrocka Hybel, and Alicja Hubalewska Dydejczyk</p>
<p>4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112<br />Alicja Hubalewska Dydejczyk, Henri J.L.M. Timmers, and Malgorzata Trofimiuk Müldner</p>
<p>4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127<br />Anouk N.A. van der Horst Schrivers, Adrienne H. Brouwers, and Thera P. Links</p>
<p>4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135<br />Malgorzata Trofimiuk Müldner and Alicja Hubalewska Dydejczyk</p>
<p>4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153<br />Alberto Signore, Kelly Luz Anzola Fuentes, and Marco Chianelli</p>
<p>5 Somatostatin Analogues in Pharmacotherapy: Introduction 164<br />Wouter W. de Herder</p>
<p>5.1 Somatostatin Analogues in Pharmacotherapy 166<br />Wouter W. de Herder</p>
<p>5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169<br />Alicja Hubalewska–Dydejczyk, Aleksandra Gilis–Januszewska, and Malgorzata Trofimiuk–Müldner</p>
<p>5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189<br />Frédérique Maire and Philippe Ruszniewski</p>
<p>5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198<br />Aleksandra Gilis Januszewska, Malgorzata Trofimiuk Müldner, Agata Jabrocka Hybel,, and Dorota Pach</p>
<p>6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207<br />John Buscombe</p>
<p>6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214<br />Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, and Dik J. Kwekkeboom</p>
<p>6.2 PRRT Dosimetry 230<br />Mark Konijnenberg</p>
<p>6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252<br />Lisa Bodei, and Giovanni Paganelli</p>
<p>6.4 Duo PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y 90 and Lu 177 Labeled Somatostatin Analogues 264<br />Richard P. Baum and Harshad R. Kulkarni</p>
<p>6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273<br />Daniel Putzer, Gerlig Widmann, Dietmar Waitz, Werner Jaschke, and Irene J. Virgolini</p>
<p>6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282<br />Agnieszka Stefa ska, Alicja Hubalewska Dydejczyk, Agata Jabrocka Hybel, and Anna Sowa Staszczak</p>
<p>7 Somatostatin Analogs: Future Perspectives and Preclinical Studies Pansomatostatins 291<br />Aikaterini Tatsi Berthold A. Nock, Theodosia Maina, and Marion de Jong</p>
<p>8 Radiolabeled Somatostatin Receptor Antagonists 305<br />Melpomeni Fani and Helmut R. Maecke</p>
<p>9 Cortistatins and Dopastatins 321<br />Manuela Albertelli and Diego Ferone</p>
<p>Index 000</p>
<p>Preface xii</p>
<p>Acknowledgements xv</p>
<p>1 Somatostatin: The History of Discovery 1<br />Malgorzata Trofimiuk Müldner and Alicja Hubalewska Dydejczyk</p>
<p>2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6<br />Marily Theodoropoulou</p>
<p>3 Somatostatin Receptors in Malignancies and Other Pathologies 21<br />Marco Volante, Adele Cassenti, Ida Rapa, Luisella Righi, and Mauro Papotti</p>
<p>4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31<br />Alberto Signore</p>
<p>4.1 Somatostatin Receptor Scintigraphy SPECT 35<br />Renata Miko ajczak and Alberto Signore</p>
<p>4.2 Molecular Imaging of Somatostatin Receptor Positive Tumors Using PET/CT 55</p>
<p>Richard P. Baum and Harshad R. Kulkarni<br />4.3 Other Radiopharmaceuticals for Imaging GEP NET 75<br />Klaas Pieter Koopmans, Rudi A. Dierckx, Philip H. Elsinga, Thera P. Links, Ido P. Kema, Helle–Brit Fiebrich, Annemieke M.E. Walekamp, Elisabeth G.E. de Vries, and Adrienne H. Brouwers</p>
<p>4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86<br />Alicja Hubalewska Dydejczyk</p>
<p>4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90<br />Anna Sowa Staszczak, Agnieszka Stefa ska, Agata Jabrocka Hybel, and Alicja Hubalewska Dydejczyk</p>
<p>4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112<br />Alicja Hubalewska Dydejczyk, Henri J.L.M. Timmers, and Malgorzata Trofimiuk Müldner</p>
<p>4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127<br />Anouk N.A. van der Horst Schrivers, Adrienne H. Brouwers, and Thera P. Links</p>
<p>4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135<br />Malgorzata Trofimiuk Müldner and Alicja Hubalewska Dydejczyk</p>
<p>4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153<br />Alberto Signore, Kelly Luz Anzola Fuentes, and Marco Chianelli</p>
<p>5 Somatostatin Analogues in Pharmacotherapy: Introduction 164<br />Wouter W. de Herder</p>
<p>5.1 Somatostatin Analogues in Pharmacotherapy 166<br />Wouter W. de Herder</p>
<p>5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169<br />Alicja Hubalewska–Dydejczyk, Aleksandra Gilis–Januszewska, and Malgorzata Trofimiuk–Müldner</p>
<p>5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189<br />Frédérique Maire and Philippe Ruszniewski</p>
<p>5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198<br />Aleksandra Gilis Januszewska, Malgorzata Trofimiuk Müldner, Agata Jabrocka Hybel,, and Dorota Pach</p>
<p>6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207<br />John Buscombe</p>
<p>6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214<br />Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, and Dik J. Kwekkeboom</p>
<p>6.2 PRRT Dosimetry 230<br />Mark Konijnenberg</p>
<p>6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252<br />Lisa Bodei, and Giovanni Paganelli</p>
<p>6.4 Duo PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y 90 and Lu 177 Labeled Somatostatin Analogues 264<br />Richard P. Baum and Harshad R. Kulkarni</p>
<p>6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273<br />Daniel Putzer, Gerlig Widmann, Dietmar Waitz, Werner Jaschke, and Irene J. Virgolini</p>
<p>6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282<br />Agnieszka Stefa ska, Alicja Hubalewska Dydejczyk, Agata Jabrocka Hybel, and Anna Sowa Staszczak</p>
<p>7 Somatostatin Analogs: Future Perspectives and Preclinical Studies Pansomatostatins 291<br />Aikaterini Tatsi Berthold A. Nock, Theodosia Maina, and Marion de Jong</p>
<p>8 Radiolabeled Somatostatin Receptor Antagonists 305<br />Melpomeni Fani and Helmut R. Maecke</p>
<p>9 Cortistatins and Dopastatins 321<br />Manuela Albertelli and Diego Ferone</p>
<p>Index 000</p>